RecruitingPhase 3

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Canada2,570 participantsStarted 2026-03-03

Plain-language summary

In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Age ≥18 years; * Hospitalized for type 1 MI, according to the 4th Universal Definition of MI; * Coronary angiogram performed; * Planned for medical management alone, without revascularization; * Willingness to participate and to attend study visits; * Expected life expectancy ≥12 months. Exclusion criteria: * Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI; * Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel; * Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.); * Confirmed or suspected spontaneous coronary artery dissection; * Concomitant indication for chronic oral anticoagulant; * Concomitant non-coronary indication for dual antiplatelet therapy; * Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician; * Previous hospitalization for MI, PCI, or CABG within 12 months; * Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor; * Unsuitability for either randomization treatment, based on the judgement of the treating physician

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Bleeding

Timeframe: From randomization to 12 months

Patient-oriented ischemic clinical endpoint

Timeframe: From randomization to 12 months

Trial details

NCT IDNCT07257198

SponsorMontreal Heart Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-01-01

Contact for this trial

Guillaume Marquis-Gravel, MD

1-514-376-3330 guillaume.marquis.gravel@umontreal.ca

View on ClinicalTrials.gov More NSTEMI - Non-ST Segment Elevation MI trials